MHPG as a predictor of antidepressant response to imipramine and maprotiline
Alan Rosenbaum, Alan F. Schatzberg, Toshihiko Maruta, Paul J. Orsulak, Jonathan Cole, EdwinL Grab, Joseph J. Schildkraut
Abstract
Alan Rosenbaum, Alan F. Schatzberg, Toshihiko Maruta, Paul J. Orsulak, Jonathan Cole, EdwinL Grab, Joseph J. Schildkraut
Abstract
To explore the hypothesis that depressed patients with low pretreatment levels of urinary 3-methoxy-4-hydroxyphenylglycol (MHPG) respond more favorably to antidepressant drugs which act on noradrenergic neuronal systems than do patients with high MHPG levels, the authors administered 150--200 mg/day of imipramine or maprotiline to 13 depressed patients. All of the 5 patients with low pretreatment MHPG levels responded to treatment compared with 1 of the 14 patients with high MHPG levels; 4 patients dropped out of the study.
OpenAlex reports 60 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
To explore the hypothesis that depressed patients with low pretreatment levels of urinary 3-methoxy-4-hydroxyphenylglycol (MHPG) respond more favorably to antidepressant drugs which act on noradrenergic neuronal systems than do patients with high MHPG levels, the authors administered 150--200 mg/day of imipramine or maprotiline to 13 depressed patients. All of the 5 patients with low pretreatment MHPG levels responded to treatment compared with 1 of the 14 patients with high MHPG levels; 4 patients dropped out of the study.
Key concepts: Maprotiline, Imipramine, Antidepressant, Medicine, Psychology, Internal medicine, Psychiatry, Hippocampus